drugset / Trial / NCT06914609
REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of ION582 in children and adults with Angelman syndrome caused by a deletion or mutation of the UBE3A gene.
Timeline
- Start
- 2025-06-10
- Primary completion
- 2027-08
- Completion
- 2030-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OBUDANERSEN SODIUM | Unknown | 40 mg | Intrathecal |
| Subject | OBUDANERSEN SODIUM | Unknown | 80 mg | Intrathecal |